ReproCELL Incorporated operates as a stem cell research company in Japan.
Flawless balance sheet with limited growth.
Share Price & News
How has ReproCELL's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6RC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 6RC exceeded the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: 6RC exceeded the German Market which returned -17.7% over the past year.
Price Volatility Vs. Market
How volatile is ReproCELL's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is ReproCELL undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6RC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 6RC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 6RC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 6RC is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6RC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6RC is overvalued based on its PB Ratio (4.4x) compared to the DE Biotechs industry average (3.6x).
How is ReproCELL forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6RC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6RC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6RC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6RC's revenue (32.6% per year) is forecast to grow faster than the German market (4.1% per year).
High Growth Revenue: 6RC's revenue (32.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6RC's Return on Equity is forecast to be high in 3 years time
How has ReproCELL performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6RC is currently unprofitable.
Growing Profit Margin: 6RC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6RC is unprofitable, and losses have increased over the past 5 years at a rate of -5.8% per year.
Accelerating Growth: Unable to compare 6RC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6RC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: 6RC has a negative Return on Equity (-12.93%), as it is currently unprofitable.
How is ReproCELL's financial position?
Financial Position Analysis
Short Term Liabilities: 6RC's short term assets (¥5.9B) exceed its short term liabilities (¥344.0M).
Long Term Liabilities: 6RC's short term assets (¥5.9B) exceed its long term liabilities (¥89.0M).
Debt to Equity History and Analysis
Debt Level: 6RC's debt to equity ratio (1.2%) is considered satisfactory.
Reducing Debt: 6RC's debt to equity ratio has reduced from 3.7% to 1.2% over the past 5 years.
Inventory Level: 6RC has a low level of unsold assets or inventory.
Debt Coverage by Assets: 6RC's debt is covered by short term assets (assets are 74.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6RC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6RC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -12.3% each year
What is ReproCELL's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6RC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 6RC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6RC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6RC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6RC's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Chikafumi Yokoyama (51yo)
Dr. Chikafumi Yokoyama, Ph.D serves as the Chief Executive Officer of ReproCELL, Inc. and has been its President since November 2005. Dr. Yokoyama joined ReproCELL Inc. in 2004 as General Manager of Busine ...
|President and Representative Director||14.25yrs||no data||1.33% ¥3.0m|
|Chief Financial Officer and Director||no data||no data||0.025% ¥55.9k|
|External Director||11.67yrs||no data||no data|
|External Standing Corporate Auditor||8yrs||no data||no data|
|External Auditor||11.67yrs||no data||no data|
|External Auditor||7.67yrs||no data||no data|
Experienced Board: 6RC's board of directors are seasoned and experienced ( 11.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.8%.
ReproCELL Incorporated's company bio, employee growth, exchange listings and data sources
- Name: ReproCELL Incorporated
- Ticker: 6RC
- Exchange: DB
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥26.206b
- Listing Market Cap: JP¥221.629m
- Shares outstanding: 71.41m
- Website: https://www.reprocell.com
Number of Employees
- ReproCELL Incorporated
- MetLife Shin-Yokohama 381 Building
- 9th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4978||JASDAQ (TSE JASDAQ)||Yes||Common Stock||JP||JPY||Jun 2013|
|6RC||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2013|
ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, and feeder cells; and 3D cell culture, labware, and drug discovery assays. The company also provides stem cell services, such as target cell isolation, iPSC reprogramming, and cell differentiation, as well as iPSC expansion, characterization, and banking services; and predictive drug discovery services in the areas of cardiac, vascular, respiratory, gastrointestinal, ADME/DMPK, skin/skin model, genitourinary, comparative pharmacology, and other assays. In addition, it offers human tissue samples, prospective collections, molecular, 3D cell, primary cell isolation, and DNA and RNA extraction services. ReproCELL Incorporated was founded in 2003 and is headquartered in Yokohama, Japan.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 22:46|
|End of Day Share Price||2020/03/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.